Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 5, 2025Frontiers in MedicineOpen Access

Impact of different endocrine therapies on bone mineral density and fracture risk in postmenopausal breast cancer patients: a meta-analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

ZWZhekun Wang

Discussion

Loading...

Member takes

Overview

Meta-analysis reveals increased fracture risk and reduced BMD in postmenopausal breast cancer patients, highlighting the impact of endocrine therapies.

Key Points

  • Different endocrine therapies influence bone mineral density and fracture risk among postmenopausal women with breast cancer.
  • Analysis of five randomized controlled trials indicates aromatase inhibitors increase fracture risk significantly.
  • The pooled odds ratio showed a 1.40 increase in fracture risk with low heterogeneity across studies.
  • Clinicians should prioritize bone health when recommending endocrine therapy options for patients.

Cite This Study

Zhekun Wang (2025) studied this question.

synapsesocial.com/papers/693231118e51979591dcdffchttps://doi.org/10.3389/fmed.2025.1665389
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Comparative bone health outcomes following tamoxifen and aromatase inhibitor therapy in breast cancer: A large-scale real-world analysis.2026
  2. 2Association Between Endocrine Therapy and Fracture Risk in Women with Breast Cancer in Germany—A Retrospective Cohort Study2026
  3. 3Differential fracture risk in breast cancer patients based on endocrine therapy and age: a nationwide cohort study2025
  4. 4Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review2018 · 133 citations
  5. 5Comparative risk of osteopenia, osteoporosis, and pathological fractures in breast cancer patients treated with steroidal versus non-steroidal aromatase inhibitors: A large-scale real-world data analysis.2026